TILs are T cells isolated from tumor fragments, ex vivo-expanded and reinfused back into pre-conditioned patients under a non-myeloablative lymphodepletion chemotherapy with high doses of interleukin-2 (IL-2) (21). The gene discussed is IL2; the disease is neoplasm.